ERBB2 and breast cancer: Similarly, tube formation assay further proved that the combination was more significant in suppressing the pro-angiogenic effect of HER2+ BC cells (Control: 12488 ± 1458 pixels, trastuzumab: 8318 ± 1310 pixels, YHD+trastuzumab 4429 ± 966 pixels, P=0.000) (Figure 2).